<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The World Health Organization (WHO) assigns <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) to RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/RSCM/<z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>, if medullary blasts are &lt;5% and peripheral blast (PB) count &lt; or =1% </plain></SENT>
<SENT sid="1" pm="."><plain>In 1103 patients with these diagnoses, we analysed survival and risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolution depending on the presence of PB </plain></SENT>
<SENT sid="2" pm="."><plain>Median survival in the group with 1% PB (n=74) was significantly lower as compared to those without PB (20 versus 47 months, p&lt;0.00005) </plain></SENT>
<SENT sid="3" pm="."><plain>Cumulative risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was significantly higher in patients showing PB (p&lt;0.00005) </plain></SENT>
<SENT sid="4" pm="."><plain>Median survival of patients with PB was not different from that of <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We therefore propose to consider patients with PB, regardless of medullary blast, as <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> </plain></SENT>
</text></document>